ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

LLAI Lunglife Ai Inc

14.40
-0.10 (-0.69%)
18 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Lunglife Ai Inc LSE:LLAI London Ordinary Share ORD USD0.0001 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.10 -0.69% 14.40 13.80 15.00 14.50 14.40 14.50 19,886 09:42:13
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

LungLife AI, INC Statement re. Silicon Valley Bank (6592S)

13/03/2023 7:00am

UK Regulatory


Lunglife Ai (LSE:LLAI)
Historical Stock Chart


From Jul 2022 to Jul 2024

Click Here for more Lunglife Ai Charts.

TIDMLLAI

RNS Number : 6592S

LungLife AI, INC

13 March 2023

LungLife AI, Inc.

(the "Company" or "LungLife")

Statement re. Silicon Valley Bank

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, is aware of media reports indicating the closure of Silicon Valley Bank ("SVB"). The Company does not hold any cash at SVB, nor does it have a banking relationship with SVB.

For further information please contact:

 
LungLife AI, Inc.                                                         www.lunglifeai.com 
Paul Pagano, CEO                                                             Via Walbrook PR 
David Anderson, CFO 
 
Investec Bank plc (Nominated Adviser                                Tel: +44 (0)20 7597 5970 
 & Broker) 
Virginia Bull / Cameron MacRitchie 
 / Lydia Zychowska 
 
Walbrook PR Limited                    Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com 
Stephanie Cuthbert / Alice Woodings                       Mob: 07980 541 893 / 07407 804 654 
 / Phillip Marriage                                                          / 07867 984 082 
 

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB(R) test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

Our Purpose is to be a driving force in the early detection to lung cancer. Our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

STREAKDAFAFDEFA

(END) Dow Jones Newswires

March 13, 2023 03:00 ET (07:00 GMT)

1 Year Lunglife Ai Chart

1 Year Lunglife Ai Chart

1 Month Lunglife Ai Chart

1 Month Lunglife Ai Chart